Compare DuPont de Nemours Inc (DD) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Invesco Ltd. — how do they compare? DuPont de Nemours Inc trades at $144.45 (market cap $19.51B), while Invesco Ltd. trades at $31.52 (market cap $13.85B). The key difference: DuPont de Nemours Inc is the larger of the two by market cap, and Invesco Ltd. pays the higher dividend (2.74%). Which is the better fit depends on your goals.
| DD | IVZ | |
|---|---|---|
Market Cap | $19.51B | $13.85B |
Sector | Basic Materials | Financials |
52-Week High | $154.59 | $32.01 |
52-Week Low | $90.24 | $20.67 |
Enterprise Value | $20.90B | $24.01B |
Dividend Yield | 1.66% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $144.65, up 2.18% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $232.80. Recent Q2 2026 earnings beat expectations with EPS of $1.88 versus $1.76 expected, driven by healthcare and industrial water demand, leading to a raised full-year 2026 outlook. The company announced strategic wins, including a membrane bioreactor system in Australia and an R&D 100 Award, highlighting innovation strength.
The stock presents growth potential from operational improvements and end-market recovery, but risks include a high P/E ratio of 62.01, net income margin of only 0.79%, and legal settlements over PFAS chemicals. Investor sentiment is positive due to earnings beats and raised guidance, though valuation concerns and liability exposures warrant caution for long-term holders.
Invesco (IVZ) trades at $31.58, down 0.5% today but near its 52-week high, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue has grown to $6.38 billion in 2025, though net income remains negative. Analyst consensus is a $32.50 price target with a mix of Buy and Hold ratings, and the firm maintains a stable dividend payout.
The outlook for IVZ is cautiously optimistic, supported by strong assets under management and positive cash flow trends. However, profitability challenges and expense pressures pose risks. Upside potential hinges on earnings improvement and market sentiment, while downside risks include margin compression and competitive pressures in asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
